Bunzz PTE LTD, a Singapore-based tech company, is thrilled to announce the successful release of “DeCipher“, a revolutionary AI-powered tool designed to transform the process of generating smart ...

Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

Bunzz, a Singapore-based web3×LLM tech web3-startup, is thrilled to announce the successful release of “DeCipher“, a revolutionary AI-powered tool designed to transform the process of generating Smart ...

Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...

SOUTH SAN FRANCISCO, Calif., April 22, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that at least 18 abstracts focused on its Decipher ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting the Decipher ® Prostate Biopsy genomic classifier (GC) may help guide treatment ...

Please provide your email address to receive an email when new articles are posted on . The genomic classifier test Decipher independently improved prognostication over clinicopathologic variables for ...

Veracyte (NASDAQ:VCYT) and Decipher Biosciences (DECI), commercial-stage precision oncology company focused on urologic cancers, inked a definitive acquisition agreement under which former will ...